Hormonal
High baseline plasma levels of specific advanced glycation end products (G-H1) and oxidation products (2-AAA) are strongly associated with greater severity of subclinical atherosclerosis (measured by CIMT, CAC, and AAC) over a 10-year follow-up in patients with type 2 diabetes.
For people with type 2 diabetes, maintaining good blood sugar control early and consistently is crucial because high blood sugar creates lasting chemical byproducts (AGEs and OxPs) that damage blood vessels for years, even after glucose levels are normalized. This damage contributes to heart disease risk long-term, highlighting the importance of early intervention and sustained management rather than just recent control.
In risk factor–adjusted multivariable regression models, G-H1 was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis.
Why this rating
Large longitudinal study (VADT substudy) with 10-year follow-up and robust multivariable adjustments, though observational in nature.
Source
Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
Aramesh Saremi et al. · Diabetes Care · 2017
DOI 10.2337/dc16-1875
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →